Legend Biotech shares climbed 6% to $21.88 by Tuesday midday after the company reported Q2 2026 results that beat expectations on revenue and earnings and delivered its first quarter of company-wide profitability. Total revenue rose 52% year over year to $387.5 million, above the $362.81 million estimate, while adjusted EPS was $0.16 versus roughly $0.07 expected. Net income reached $33.2 million compared with a net loss of $125.4 million a year earlier, with adjusted net income at $63.1 million and operating income at $57.7 million. The company said profitability was achieved on both an IFRS (international accounting standards) and adjusted basis. A sharp drop in unrealized foreign-exchange losses to $0.6 million from $110.9 million a year earlier also supported the swing. CARVYKTI, a CAR-T (engineered immune-cell therapy) for multiple myeloma, remained the core driver, with net trade sales up 50% year over year to $657 million, including 32% growth in the United States and 128% growth outside the United States. The therapy is now available at 348 treatment sites across 19 markets, with Ireland the latest launch, and management reiterated peak annual sales potential above $5 billion. Legend ended the quarter with about $965 million in cash, cash equivalents and time deposits, no long-term debt, and roughly $212 million in net proceeds from a June public offering. The company also reported first clinical proof-of-concept for LB2501 in relapsed or refractory B-cell non-Hodgkin lymphoma and plans a U.S. IND (application to begin human testing) filing by year-end. Investors are also watching the leadership transition after Alan Bash became interim CEO following the departure of former CEO Ying Huang last month. The source said traders should look for whether the stock holds its gains and for updated analyst commentary, with the consensus target at $52.10 alongside 5 strong buys, 6 buys and 4 holds.